S&P 500   3,262.99 (-1.70%)
DOW   27,060.17 (-2.16%)
QQQ   262.80 (-1.53%)
AAPL   105.16 (-1.57%)
MSFT   197.77 (-1.31%)
FB   246.50 (-2.39%)
GOOGL   1,427.95 (-1.59%)
AMZN   2,925.21 (-1.01%)
NVDA   483.31 (-0.87%)
TSLA   450.83 (+1.96%)
BABA   267.99 (-1.62%)
CGC   15.86 (-3.06%)
GE   6.46 (-6.10%)
MU   49.13 (-3.17%)
AMD   75.83 (+1.20%)
T   28.57 (-1.24%)
F   6.92 (-4.29%)
ACB   6.33 (-3.06%)
GILD   64.16 (-1.37%)
NFLX   470.40 (+0.09%)
DIS   125.75 (-2.24%)
BAC   24.55 (-2.62%)
BA   157.05 (-2.54%)
S&P 500   3,262.99 (-1.70%)
DOW   27,060.17 (-2.16%)
QQQ   262.80 (-1.53%)
AAPL   105.16 (-1.57%)
MSFT   197.77 (-1.31%)
FB   246.50 (-2.39%)
GOOGL   1,427.95 (-1.59%)
AMZN   2,925.21 (-1.01%)
NVDA   483.31 (-0.87%)
TSLA   450.83 (+1.96%)
BABA   267.99 (-1.62%)
CGC   15.86 (-3.06%)
GE   6.46 (-6.10%)
MU   49.13 (-3.17%)
AMD   75.83 (+1.20%)
T   28.57 (-1.24%)
F   6.92 (-4.29%)
ACB   6.33 (-3.06%)
GILD   64.16 (-1.37%)
NFLX   470.40 (+0.09%)
DIS   125.75 (-2.24%)
BAC   24.55 (-2.62%)
BA   157.05 (-2.54%)
S&P 500   3,262.99 (-1.70%)
DOW   27,060.17 (-2.16%)
QQQ   262.80 (-1.53%)
AAPL   105.16 (-1.57%)
MSFT   197.77 (-1.31%)
FB   246.50 (-2.39%)
GOOGL   1,427.95 (-1.59%)
AMZN   2,925.21 (-1.01%)
NVDA   483.31 (-0.87%)
TSLA   450.83 (+1.96%)
BABA   267.99 (-1.62%)
CGC   15.86 (-3.06%)
GE   6.46 (-6.10%)
MU   49.13 (-3.17%)
AMD   75.83 (+1.20%)
T   28.57 (-1.24%)
F   6.92 (-4.29%)
ACB   6.33 (-3.06%)
GILD   64.16 (-1.37%)
NFLX   470.40 (+0.09%)
DIS   125.75 (-2.24%)
BAC   24.55 (-2.62%)
BA   157.05 (-2.54%)
S&P 500   3,262.99 (-1.70%)
DOW   27,060.17 (-2.16%)
QQQ   262.80 (-1.53%)
AAPL   105.16 (-1.57%)
MSFT   197.77 (-1.31%)
FB   246.50 (-2.39%)
GOOGL   1,427.95 (-1.59%)
AMZN   2,925.21 (-1.01%)
NVDA   483.31 (-0.87%)
TSLA   450.83 (+1.96%)
BABA   267.99 (-1.62%)
CGC   15.86 (-3.06%)
GE   6.46 (-6.10%)
MU   49.13 (-3.17%)
AMD   75.83 (+1.20%)
T   28.57 (-1.24%)
F   6.92 (-4.29%)
ACB   6.33 (-3.06%)
GILD   64.16 (-1.37%)
NFLX   470.40 (+0.09%)
DIS   125.75 (-2.24%)
BAC   24.55 (-2.62%)
BA   157.05 (-2.54%)
Log in
NASDAQ:TXMD

TherapeuticsMD Stock Forecast, Price & News

$1.42
-0.04 (-2.41 %)
(As of 09/21/2020 09:38 AM ET)
Add
Compare
Today's Range
$1.41
Now: $1.42
$1.44
50-Day Range
$1.33
MA: $1.56
$2.05
52-Week Range
$0.85
Now: $1.42
$4.32
Volume1,284 shs
Average Volume4.59 million shs
Market Capitalization$385.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. is headquartered in Boca Raton, Florida.
Read More
TherapeuticsMD logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TXMD
Previous SymbolNYSEMKT:TXMD
CUSIPN/A
Phone561-961-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$49.65 million
Book Value$0.03 per share

Profitability

Net Income$-176,150,000.00
Net Margins-304.01%

Miscellaneous

Employees348
Market Cap$385.30 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$1.42
-0.04 (-2.41 %)
(As of 09/21/2020 09:38 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

How has TherapeuticsMD's stock price been impacted by Coronavirus (COVID-19)?

TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TXMD shares have decreased by 4.6% and is now trading at $1.45.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of TherapeuticsMD?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TherapeuticsMD
.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for TherapeuticsMD
.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) posted its earnings results on Thursday, August, 6th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.02. The company had revenue of $10.70 million for the quarter, compared to analysts' expectations of $11.93 million. TherapeuticsMD had a negative net margin of 304.01% and a negative return on equity of 1,170.63%.
View TherapeuticsMD's earnings history
.

What price target have analysts set for TXMD?

6 Wall Street analysts have issued 1-year price objectives for TherapeuticsMD's shares. Their forecasts range from $1.20 to $15.00. On average, they anticipate TherapeuticsMD's stock price to reach $7.24 in the next twelve months. This suggests a possible upside of 399.3% from the stock's current price.
View analysts' price targets for TherapeuticsMD
.

Who are some of TherapeuticsMD's key competitors?

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Novavax (NVAX), Cleveland-Cliffs (CLF), Micron Technology (MU) and NIO (NIO).

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the following people:
  • Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 49, Pay $1.22M)
  • Mr. John C. K. Milligan IV, Pres & Sec. (Age 58, Pay $794.68k)
  • Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 62, Pay $659.3k)
  • Mr. Mitchell L. Krassan, Exec. VP and Chief Strategy & Performance Officer (Age 54, Pay $560.53k)
  • Mr. Michael Donegan, VP of Fin. (Age 52, Pay $378.3k)

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (5.48%), Sanders Morris Harris LLC (1.37%), Stifel Financial Corp (1.03%), Nuveen Asset Management LLC (0.70%), Charles Schwab Investment Management Inc. (0.55%) and Bank of New York Mellon Corp (0.34%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson.
View institutional ownership trends for TherapeuticsMD
.

Which major investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, FMR LLC, Stifel Financial Corp, Spark Investment Management LLC, US Bancorp DE, Advisor Group Holdings Inc., Sanders Morris Harris LLC, and Commonwealth Equity Services LLC.
View insider buying and selling activity for TherapeuticsMD
.

Which major investors are buying TherapeuticsMD stock?

TXMD stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., MCF Advisors LLC, Raymond James Financial Services Advisors Inc., SG Americas Securities LLC, Jane Street Group LLC, Charles Schwab Investment Management Inc., Two Sigma Advisers LP, and Swiss National Bank. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio, and Tommy G Thompson.
View insider buying and selling activity for TherapeuticsMD
.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $1.45.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $394.83 million and generates $49.65 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 348 workers across the globe.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is www.therapeuticsmd.com.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.